Literature DB >> 1722107

Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.

M Maeda1, R D Knowles, E S Kleinerman.   

Abstract

Muramyl tripeptide phosphatidylethanolamine (MTP-PE), a synthetic lipophilic analogue of muramyl dipeptide (MDP), can be incorporated into the lipid membrane of liposomes. Liposomes containing MTP-PE (L-MTP-PE) stimulated monocytes to selectively kill tumors, but not normal cells in vitro. Furthermore, the activation of monocyte tumoricidal function was demonstrated following the i.v. infusion of L-MTP-PE in a phase I trial with cancer patients. The purpose of this study was to determine the mechanism by which L-MTP-PE activates monocytes. Monocyte tumoricidal function is linked to both interleukin-1 (IL-1) and tumor necrosis factor (TNF). Therefore, normal human monocytes were incubated for various times with L-MTP-PE, empty liposomes, or medium in the presence or absence of gamma interferon (IFN-gamma). The supernatants were removed and assayed for TNF and IL-1 using the L929 and D10.G4.1 assays, respectively. TNF was detected after a 4 hr incubation with L-MTP-PE but not with empty liposomes or medium. TNF secretion peaked at 8 hr and was sustained for up to 72 hr. A 4-fold increase in TNF mRNA levels was demonstrated after 8 hr. An increased level of IL-1 beta mRNA was detected after a 4 hr incubation, but only low level IL-1 secretion was detected in monocytes incubated with L-MTP-PE. Adherent monocytes were frozen and thawed to release intracellular IL-1. Intracellular IL-1 was significantly increased in monocytes incubated with L-MTP-PE. Intracellular IL-1 levels peaked by 8 hr and decreased by 72 hr. Activators were then assayed in the presence or absence of IFN-gamma.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1722107     DOI: 10.3727/095535491820873740

Source DB:  PubMed          Journal:  Cancer Commun        ISSN: 0955-3541


  11 in total

Review 1.  Mifamurtide: a review of its use in the treatment of osteosarcoma.

Authors:  James E Frampton
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

2.  Differential roles of inflammation and apoptosis in initiation of mid-gestational abortion in malaria-infected C57BL/6 and A/J mice.

Authors:  D Sarr; T C Bracken; S O Owino; C A Cooper; G M Smith; T Nagy; J M Moore
Journal:  Placenta       Date:  2015-04-28       Impact factor: 3.481

3.  Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.

Authors:  T Asano; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

4.  Toward a drug development path that targets metastatic progression in osteosarcoma.

Authors:  Chand Khanna; Timothy M Fan; Richard Gorlick; Lee J Helman; Eugenie S Kleinerman; Peter C Adamson; Peter J Houghton; William D Tap; Danny R Welch; Patricia S Steeg; Glenn Merlino; Poul H B Sorensen; Paul Meltzer; David G Kirsch; Katherine A Janeway; Brenda Weigel; Lor Randall; Stephen J Withrow; Melissa Paoloni; Rosandra Kaplan; Beverly A Teicher; Nita L Seibel; Malcolm Smith; Aykut Uren; Shreyaskumar R Patel; Jeffrey Trent; Sharon A Savage; Lisa Mirabello; Denise Reinke; Donald A Barkaukas; Mark Krailo; Mark Bernstein
Journal:  Clin Cancer Res       Date:  2014-05-06       Impact factor: 12.531

5.  Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.

Authors:  M Maeda; T Asano; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

6.  Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.

Authors:  D Risin; E S Kleinerman; Y Umezu; R P Pizzini; C M Balch; N R Pellis
Journal:  Cancer Immunol Immunother       Date:  1995-01       Impact factor: 6.968

7.  Antitumor effects of liposomal IL1 alpha and TNF alpha against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice.

Authors:  M Saito; D Fan; L B Lachman
Journal:  Clin Exp Metastasis       Date:  1995-07       Impact factor: 5.150

8.  Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?

Authors:  W Fujimaki; J R Griffin; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

9.  Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.

Authors:  T Asano; W Fujimaki; A McWatters; T An; K Matsushima; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993-11       Impact factor: 6.968

Review 10.  Managing sarcoma: where have we come from and where are we going?

Authors:  Jenna S Bleloch; Reyna D Ballim; Serah Kimani; Jeannette Parkes; Eugenio Panieri; Tarryn Willmer; Sharon Prince
Journal:  Ther Adv Med Oncol       Date:  2017-09-20       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.